Bulletin
Investor Alert

Market Pulse Archives

May 8, 2020, 2:47 p.m. EDT

Government to test remdesivir with Lilly drug in COVID-19 patients

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Gilead Sciences Inc. (GILD)
  • X
    Eli Lilly & Co. (LLY)
  • X
    Regeneron Pharmaceuticals Inc. (REGN)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.'s /zigman2/quotes/210293917/composite GILD -0.33% remdesivir in combination with Eli Lilly & Co.'s /zigman2/quotes/200106384/composite LLY -0.48% rheumatoid arthritis drug Olumiant in COVID-19 patients as part of the next phase of the randomized, controlled clinical trial that led to the authorization of remdesivir. This study will enroll 1,000 people at more than 100 sites in the U.S. and abroad, to "examine if adding an anti-inflammatory agent to the remdesivir regimen can provide additional benefit for patients," NIAID director Dr. Anthony Fauci said in a statement. The topline results from the remdesivir trial helped make up the basis of the Food and Drug Administration's (FDA) emergency use authorization for the drug last week. A number of medicines that have been previously approved by the FDA to treat rheumatoid arthritis have been proposed as possible COVID-19 treatments, including Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN -0.56% and Sanofi's /zigman2/quotes/201967021/composite SNY -1.02% Kevzara and Roche Holding AG's /zigman2/quotes/206324342/delayed CH:ROG -0.24% Actemra. Olumiant, which was developed by Incyte Corp. /zigman2/quotes/204510994/composite INCY -0.78% and is licensed to Lilly, brought in $427 million in sales in 2019 for the Indianapolis-based drugmaker. Only two types of therapies - remdesivir and hydroxycholorquine and chlorquine - are authorized by the FDA as COVID-19 treatments. Year-to-date, Gilead's stock has gained 18.6%, while shares of Lilly are up 16.6%. The S&P 500 /zigman2/quotes/210599714/realtime SPX +0.42% is down 10.8%.

/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 69.83
-0.23 -0.33%
Volume: 7.60M
July 29, 2021 4:00p
P/E Ratio
307.76
Dividend Yield
4.07%
Market Cap
$87.87 billion
Rev. per Employee
$1.81M
loading...
/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 245.33
-1.18 -0.48%
Volume: 1.92M
July 29, 2021 4:05p
P/E Ratio
36.72
Dividend Yield
1.39%
Market Cap
$236.41 billion
Rev. per Employee
$701,137
loading...
/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 583.13
-3.28 -0.56%
Volume: 361,434
July 29, 2021 4:00p
P/E Ratio
16.50
Dividend Yield
N/A
Market Cap
$62.48 billion
Rev. per Employee
$931,393
loading...
/zigman2/quotes/201967021/composite
US : U.S.: Nasdaq
$ 51.53
-0.53 -1.02%
Volume: 1.92M
July 29, 2021 4:00p
P/E Ratio
9.41
Dividend Yield
2.65%
Market Cap
$129.71 billion
Rev. per Employee
$413,288
loading...
/zigman2/quotes/206324342/delayed
CH : Switzerland: SWX
CHF 347.60
-0.85 -0.24%
Volume: 646,771
July 29, 2021 5:31p
P/E Ratio
21.39
Dividend Yield
2.62%
Market Cap
CHF303.69 billion
Rev. per Employee
CHF574,809
loading...
/zigman2/quotes/204510994/composite
US : U.S.: Nasdaq
$ 77.40
-0.61 -0.78%
Volume: 1.53M
July 29, 2021 4:00p
P/E Ratio
35.73
Dividend Yield
N/A
Market Cap
$17.16 billion
Rev. per Employee
$1.50M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,419.15
+18.51 +0.42%
Volume: 2.01B
July 29, 2021 5:13p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.